Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.8800 +0.0199 (+2.31%) 04/02/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.9000 +0.0200 (+2.27%) 19:19 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8800
Day High
0.9000
Open 0.9000
Previous Close 0.8601 0.8601
Volume 5,200 5,200
Avg Vol 13,310 13,310
Stochastic %K 6.50% 6.50%
Weighted Alpha -45.56 -45.56
5-Day Change -0.0910 (-9.37%) -0.0910 (-9.37%)
52-Week Range 0.8600 - 1.5999 0.8600 - 1.5999
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,822
  • Shares Outstanding, K 3,281
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,830 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.05
  • Most Recent Earnings $-1.17 on 03/03/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +128,176.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8600 +2.33%
on 04/01/25
Period Open: 1.0700
1.0900 -19.27%
on 03/03/25
-0.1900 (-17.76%)
since 02/28/25
3-Month
0.8600 +2.33%
on 04/01/25
Period Open: 1.0900
1.5495 -43.21%
on 02/06/25
-0.2100 (-19.27%)
since 01/02/25
52-Week
0.8600 +2.33%
on 04/01/25
Period Open: 1.5000
1.5999 -45.00%
on 04/09/24
-0.6200 (-41.33%)
since 04/02/24

Most Recent Stories

More News
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

ARTL : 0.8800 (+2.31%)
New Strong Sell Stocks for March 28th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Aperam S.A. APEMY is a stainless steel company. The Zacks Consensus Estimate for its current year earnings has been revised 13.1%...

CIGI : 124.06 (+0.94%)
ARTL : 0.8800 (+2.31%)
APEMY : 33.3100 (-0.43%)
New Strong Sell Stocks for March 6th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Artelo Biosciences, Inc. ARTL is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year...

ARTL : 0.8800 (+2.31%)
KRP : 14.31 (+0.63%)
KW : 8.61 (+0.82%)
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

ARTL : 0.8800 (+2.31%)
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland 

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Presents Preliminary Data on ART27.13 for Cancer-Related Anorexia at International Conference

Artelo Biosciences presented positive preliminary data on ART27.13 for cancer-related anorexia at an international conference.Quiver AI SummaryArtelo Biosciences, Inc. has announced preliminary results...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

ARTL : 0.8800 (+2.31%)
Artelo Biosciences to Present Innovations in Cannabinoid-Derived Drug Development at Boston Summit

Artelo Biosciences will present innovative drug development data at the Cannabinoid-Derived Drug Development Summit in Boston.Quiver AI SummaryArtelo Biosciences, Inc. announced that Professor Saoirse...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit 

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

ARTL : 0.8800 (+2.31%)
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy ...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022 ...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 0.8800 (+2.31%)
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland

SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...

ARTL : 0.8800 (+2.31%)

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 0.9133
2nd Resistance Point 0.9067
1st Resistance Point 0.8933
Last Price 0.8800
1st Support Level 0.8733
2nd Support Level 0.8667
3rd Support Level 0.8533

See More

52-Week High 1.5999
Fibonacci 61.8% 1.3173
Fibonacci 50% 1.2299
Fibonacci 38.2% 1.1426
Last Price 0.8800
52-Week Low 0.8600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades